M E M O R A N D U M

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS

---

DATE: September 8, 2000

FROM: Nasser Mahmud 9/11/00
Chief, Regulatory Support Branch
Division of Labeling and Program Support

THROUGH: Peter Rickman 9/11/00
Acting Director, Division of Labeling and Program Support

SUBJECT: Statistical Report - Month of August, 2000

TO: See Below

This memorandum represents the Office of Generic Drugs' statistical report for August, 2000.

Tables I through III detail quantitative information about OGD's receipts, actions, and pending review status for both original and supplemental (CMC and labeling) applications for the past month and for the 11 preceding months. Following the tables, graphic presentations of selective quantitative data are provided. These graphs allow comparisons to similar data dating back to 1992. Where appropriate, the graphs have been modified to reflect the change of AADAs to ANDAs as a result of the elimination of Section 507 of the FD&C Act under FDAMA.

Approvals for the month of August include 25 new generic full approvals and 3 tentative approvals. Of the 28 approvals, 3 applications were approved as first generics. In addition, OGD approved 3 new strength supplements. Separate lists of the approvals for the month of August follow the graphic presentations.

90S-0308 RPT 1

## Center for Drug Evaluation and Research - Office of Generic Drugs

Table I

### Quantitative Report

### ORIGINAL APPLICATIONS

| | Sep-99 | Oct-99 | Nov-99 | Dec-99 | Jan-00 | Feb-00 | Mar-00 | Apr-00 | May-00 | Jun-00 | Jul-00 | Aug-00 | TOTAL | AVG LAST 12 MOS | AVG LAST 3 MOS | AVG PRIOR YEAR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **-- RECEIPTS --** | | | | | | | | | | | | | | | | |
| TOTAL ORIGINALS | 25 | 17 | 17 | 46 | 19 | 24 | 20 | 18 | 48 | 38 | 19 | 22 | 313 | 26 | 26 | 27 |
| AMENDMENTS | 144 | 112 | 139 | 131 | 112 | 132 | 170 | 124 | 144 | 138 | 140 | 145 | 1631 | 136 | 141 | 128 |
| - MAJOR | 74 | 48 | 57 | 62 | 40 | 61 | 69 | 53 | 64 | 56 | 58 | 73 | 715 | 60 | 62 | 60 |
| - MINOR | 43 | 33 | 48 | 34 | 44 | 47 | 60 | 39 | 46 | 49 | 52 | 54 | 549 | 46 | 52 | 31 |
| - FACSIMILE ** | 27 | 31 | 34 | 35 | 28 | 24 | 41 | 32 | 34 | 33 | 30 | 18 | 367 | 31 | 27 | 37 |
| **-- ACTIONS --** | | | | | | | | | | | | | | | | |
| APPROVALS | 13 | 12 | 19 | 15 | 18 | 21 | 21 | 18 | 23 | 25 | 14 | 25 | 224 | 19 | 21 | 18 |
| TENTATIVE APPROVALS+ | 4 | 8 | 3 | 2 | 3 | 5 | 9 | 10 | 5 | 5 | 6 | 3 | 63 | 5 | 5 | 6 |
| NOT APPROVABLE | 42 | 49 | 38 | 46 | 28 | 60 | 72 | 34 | 41 | 36 | 44 | 51 | 541 | 45 | 44 | 39 |
| FACSIMILE REQUEST** | 10 | 19 | 16 | 19 | 13 | 18 | 34 | 11 | 16 | 16 | 5 | 13 | 190 | 16 | 11 | 19 |
| REFUSE TO RECEIVE | 2 | 4 | 6 | 0 | 4 | 7 | 10 | 1 | 6 | 7 | 9 | 4 | 60 | 5 | 7 | 7 |
| WITHDRAWALS | 59 | 25 | 7 | 5 | 43 | 9 | 14 | 6 | 45 | 55 | 8 | 23 | 299 | 25 | 29 | 31 |
| - OF APPROVED | 47 | 15 | 3 | 3 | 37 | 4 | 11 | 3 | 14 | 22 | 1 | 19 | 179 | 15 | 14 | 25 |
| - OF UNAPPROVED | 12 | 10 | 4 | 2 | 6 | 5 | 3 | 3 | 31 | 33 | 7 | 4 | 120 | 10 | 15 | 7 |
| **-- REVIEW STATUS --** | | | | | | | | | | | | | | | | |
| AWAITING OGD ACTION (TOTAL)*** | 427 | 399 | 415 | 438 | 414 | 398 | 376 | 377 | 397 | 413 | 416 | 405 | | 406 | 411 | 422 |
| AWAITING OGD ACTION (> 180 DAYS)*** | 90 | 67 | 71 | 74 | 82 | 73 | 68 | 63 | 57 | 64 | 44 | 47 | | 67 | 52 | 93 |
| AWAITING OGD ACTION (<=180 DAYS)*** | 337 | 332 | 344 | 364 | 332 | 325 | 308 | 314 | 340 | 349 | 372 | 358 | | 340 | 360 | 329 |

** Facsimile policy went into effect in January of 1997

*** In September, 1991, the Office of Generic Drugs started implementation of its Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. Review status figures reported since this date exclude suspended applications.
As of 31 August 2000, 1 original application and 11 supplements were suspended.
Upon completion of validity assessments, suspended applications may be returned to active pending status.

+ Note: Tentative approvals are counted as approvals subsequently when approved.

Center for Drug Evaluation and Research - Office of Generic Drugs

Quantitative Report

Table II

## POST APPROVAL SUBMISSIONS TO APPLICATIONS (CHEMISTRY)

| | Sep-99 | Oct-99 | Nov-99 | Dec-99 | Jan-00 | Feb-00 | Mar-00 | Apr-00 | May-00 | Jun-00 | Jul-00 | Aug-00 | TOTAL | AVG LAST 12 MOS | AVG LAST 3 MOS | AVG PRIOR YEAR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| --RECEIPTS-- | | | | | | | | | | | | | | | | |
| ORIGINAL SUPPLEMENTS | 100 | 139 | 161 | 116 | 173 | 297 | 166 | 152 | 156 | 224 | 276 | 240 | 2200 | 183 | 247 | 230 |
| AMENDMENTS TO SUPPLEMENTS | 170 | 118 | 198 | 200 | 242 | 579 | 293 | 229 | 205 | 295 | 337 | 292 | 3158 | 263 | 308 | 218 |
| --SUPPLEMENTAL ACTIONS-- ** | | | | | | | | | | | | | | | | |
| APPROVALS | 91 | 81 | 176 | 185 | 216 | 143 | 201 | 189 | 334 | 112 | 268 | 167 | 2163 | 180 | 182 | 200 |
| APPROVABLE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOT APPROVABLE | 53 | 149 | 42 | 98 | 136 | 109 | 128 | 32 | 96 | 92 | 56 | 70 | 1061 | 88 | 73 | 107 |
| WITHDRAWALS | 12 | 14 | 18 | 19 | 27 | 6 | 69 | 17 | 35 | 13 | 26 | 18 | 274 | 23 | 19 | 27 |
| --REVIEW STATUS-- | | | | | | | | | | | | | | | | |
| SUPPLEMENTS AWAITING OGD ACTION (TOTAL) * | 1404 | 1413 | 1331 | 1257 | 1119 | 1353 | 1223 | 1242 | 1058 | 1094 | 1104 | 1183 | | 1232 | 1127 | 1579 |
| SUPPLEMENTS AWAITING OGD ACTION (>180 DAYS) | 93 | 95 | 156 | 178 | 156 | 188 | 132 | 87 | 54 | 102 | 84 | 124 | | 121 | 103 | 171 |
| SUPPLEMENTS AWAITING OGD ACTION (<=180 DAYS) | 1311 | 1318 | 1175 | 1079 | 963 | 1165 | 1091 | 1155 | 1004 | 992 | 1020 | 1059 | | 1111 | 1024 | 1409 |

* In September, 1991, the Office of Generic Drugs started implementation of its Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. Review status figures reported since this date exclude suspended applications.
As of 31 August 2000, 1 original application and 11 supplements were suspended.
Upon completion of validity assessments, suspended applications may be returned to active pending status.

** Supplemental actions between May 1999 and April 2000 had previously been underreported due to an electronic report error.

Center for Drug Evaluation and Research - Office of Generic Drugs

Quantitative Report

Table III

## POST APPROVAL SUBMISSIONS TO APPLICATIONS (LABELING)

| | Sep-99 | Oct-99 | Nov-99 | Dec-99 | Jan-00 | Feb-00 | Mar-00 | Apr-00 | May-00 | Jun-00 | Jul-00 | Aug-00 | TOTAL | AVG LAST 12 MOS | AVG LAST 3 MOS | AVG PRIOR YEAR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **--RECEIPTS--** | | | | | | | | | | | | | | | | |
| ORIGINAL SUPPLEMENTS | 45 | 77 | 45 | 25 | 22 | 47 | 43 | 35 | 46 | 24 | 64 | 62 | 535 | 45 | 50 | 47 |
| AMENDMENTS TO SUPPLEMENTS | 84 | 101 | 39 | 61 | 31 | 53 | 64 | 46 | 55 | 45 | 80 | 67 | 726 | 61 | 64 | 53 |
| **--SUPPLEMENTAL ACTIONS--** | | | | | | | | | | | | | | | | |
| APPROVALS | 63 | 49 | 75 | 42 | 40 | 38 | 43 | 35 | 27 | 22 | 36 | 72 | 542 | 45 | 43 | 47 |
| APPROVABLE | 6 | 6 | 13 | 3 | 4 | 12 | 2 | 13 | 4 | 1 | 3 | 5 | 72 | 6 | 3 | 7 |
| NOT APPROVABLE | 13 | 15 | 23 | 8 | 9 | 7 | 11 | 11 | 13 | 24 | 4 | 9 | 147 | 12 | 12 | 15 |
| WITHDRAWALS | 6 | 1 | 5 | 0 | 0 | 0 | 1 | 1 | 0 | 8 | 3 | 1 | 26 | 2 | 4 | 4 |
| **--REVIEW STATUS--** | | | | | | | | | | | | | | | | |
| SUPPLEMENTS AWAITING OGD ACTION (TOTAL) | 242 | 284 | 218 | 229 | 205 | 213 | 215 | 214 | 224 | 224 | 265 | 253 | | 232 | 247 | 310 |
| SUPPLEMENTS AWAITING OGD ACTION (>180 DAYS) | 90 | 81 | 81 | 86 | 83 | 83 | 77 | 80 | 87 | 83 | 82 | 85 | | 83 | 83 | 115 |
| SUPPLEMENTS AWAITING OGD ACTION (<=180 DAYS) | 152 | 203 | 137 | 143 | 122 | 130 | 138 | 134 | 137 | 141 | 183 | 168 | | 149 | 164 | 195 |

* In September, 1991, the Office of Generic Drugs started implementation of its Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. Review status figures reported since this date exclude suspended applications.
As of 31 August 2000, 1 original application and 11 supplements were suspended.
Upon completion of validity assessments, suspended applications may be returned to active pending status.


Original ANDAs Received
ANDAs
6-Month Moving Average
60
50
40
30
20
10
0
Actual Counting System
August 31, 2000


Actions on Original ANDAs
6-Month Moving Avg.
Tentative Approval
FAX Amendments
Approved
Not Approvable
160
140
120
100
80
60
40
20
0
NOTE: TENTATIVE APPROVALS ARE APPLICATIONS THAT HAVE BEEN APPROVED BY THE OFFICE PENDING PATENT EXPIRATION. TENTATIVE APPROVALS ARE COUNTED AS APPROVALS SUBSEQUENTLY WHEN APPROVED.
Actual Counting System


Original ANDAs Approved or Tentatively Approved
6-Month Moving Avg
Tentative Approval
APPROVED
50
40
30
20
10
0
NOTE: TENTATIVE APPROVALS ARE APPLICATIONS THAT HAVE BEEN APPROVED BY THE OFFICE PENDING PATENT EXPIRATION. TENTATIVE APPROVALS ARE COUNTED AS APPROVALS SUBSEQUENTLY WHEN APPROVED. FOR EXAMPLE 44 OF 66 APPROVALS FOR FEBRUARY 1996 WERE PREVIOUSLY TENTATIVELY APPROVED. THE LARGE NUMBER OF APPROVALS RESULTED FROM A DRUG COMING OFF PATENT IN FEBRUARY.
Actual Counting System


Original ANDAs Pending Per Month
> 180 Days
< 180 Days
700
600
500
400
300
200
100
0
Actual Counting System

## *Chemistry, Manufacturing & Controls Supplements Awaiting OGD Action*




Please note that abrupt changes in the level of pending supplements (e.g. the increase in September 1994) are the result of global submissions to all applications held by a single firm. Changes other than these will be explained separately.

## *Labeling Supplements Awaiting OGD Action*




## Percent Approved and Not-Approvable Per Month

**(Original Applications)**




*Actual Counting System*

## *Median ANDA CMC Supplement Review Time (Months)*




1-Times correspond to actual applications received. The new ANDA/AADA submission policy that went into effect 11/91 allows certain variations in a drug product to be included in a single application.

2-In September, 1991 the OGD started implementation of the Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. AIP time has been subtracted from review time above for the period after 9/91. However, before the AIP went into effect, the review of many applications suspected of containing fraudulent data were suspended. These suspensions were not recorded in the MIS and are not reflected in the above chart.

**Note: Global Supplements Collapsed**

## Percent of Original Submissions with Refuse to Receive Action

**By Month of Receipt**




Status as of September 5,2000, Percentages for recent months may increase due to future RR actions

*(Actual counting system)*

## Median ANDA Review Cycle (Months)

**(Original Applications & Major Amendments)**




1- Times correspond to actual applications received. The new ANDA/AADA submission policy that went into effect 1/1/91 allows certain variations in a drug product to be included in a single application

2-In September, 1991 the OGD started implementation of the Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. AIP time has been subtracted from review time above for the period after 9/91. However, before the AIP went into effect, the review of many applications suspected of containing fraudulent data were suspended. These suspensions were not recorded in the MIS and are not reflected in the above chart

## Original ANDAs Pending > 180 Days




*Actual Counting System*

## ANDA *CMC* Supplements Pending > 180 Days




Please note that abrupt changes in the level of pending supplements (e.g. the increase in September 1994) are the result of global submissions to all applications held by a single firm. Changes other than these will be explained separately


Mean and Median ANDA Review Cycle (Months)
(Original Applications & Major Amendments)
16
14
12
10
8
6
4
2
0
Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul
91
92
93
94
95
96
97
98
99
00
Mean
Median
1-Times correspond to actual applications received. The new ANDA/AADA submission policy that went into effect 1/1/91 allows certain variations in a drug product to be included in a single application.
2-In September, 1991 the CGD started implementation of the Application Integrity Policy by suspending review of applications suspected of being tainted by fraud. AIP time has been subtracted from review time above for the period after 9/91. However, before the AIP went into effect, the review of many applications suspected of containing fraudulent data were suspended. These suspensions were not recorded in the MIS and are not reflected in the above chart.

# Office Of Generic Drugs ANDAs Approvals



| | | | | |
|---|---|---|---|---|
| 1. | 75-473 | LEVOBUNOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION, USP 0.25% | NOVEX PHARMA | 8/3/00 |
| 2. | 75-475 | LEVOBUNOLOL HYDROCHLORIDE OPHTHALMIC SOLUTION, USP 0.5% | NOVEX PHARMA | 8/3/00 |
| 3. | 75-048 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | GENEVA PHARMACEUTICALS, INC. | 8/22/00 |
| 4. | 75-369 | ENALAPRIL MALEATE TABLETS, USP 10 MG 20 MG | KRKA, d.d., NOVO MESTO | 8/22/00 |
| 5. | 75-370 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG | KRKA, d.d., NOVO MESTO | 8/22/00 |
| 6. | 75-456 | ENALAPRILAT INJECTION 1.25 MG/ML (SYRINGE) | ABBOTT LABORATORIES | 8/22/00 |
| 7. | 75-458 | ENALAPRILAT INJECTION 1.25 MG/ML (VIALS) | ABBOTT LABORATORIES | 8/22/00 |
| 8. | 75-459 | ENALAPRIL MALEATE TABLETS USP 10 MG 20 MG | LEK PHARMACEUTICAL AND CHEMICAL CO. d.d. | 8/22/00 |
| 9. | 75-472 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | GENPHARM INC. | 8/22/00 |
| 10. | 75-479 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | TEVA PHARMACEUTICALS, USA | 8/22/00 |
| 11. | 75-480 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | MYLAN PHARMACEUTICALS, INC. | 8/22/00 |
| 12. | 75-482 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | ZENITH GOLDLINE PHARMACEUTICALS, INC. | 8/22/00 |

| | | | | |
|---|---|---|---|---|
| 13. | 75-483 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | WOCKHARDT AMERICAS, INC. | 8/22/00 |
| 14. | 75-496 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG | LEK PHARMACEUTICAL AND CHEMICAL CO. d.d. | 8/22/00 |
| 15. | 75-501 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | CHELSEA LABORATORIES, INC. | 8/22/00 |
| 16. | 75-556 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | RANBAXY LABORATORIES LIMITED | 8/22/00 |
| 17. | 75-571 | ENALAPRILAT INJECTION 1.25 MG/ML (VIALS) | FAULDING PHARMACEUTICAL CO. | 8/22/00 |
| 18. | 75-578 | ENALAPRILAT INJECTION 1.25 MG/ML (VIALS) | GENSIA SICOR PHARMACEUTICALS, INC. | 8/22/00 |
| 19. | 75-583 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | APOTHECON, INC. | 8/22/00 |
| 20. | 75-621 | ENALAPRIL MALEATE TABLETS, USP 2.5 MG 5 MG 10 MG 20 MG | EON LABS MANUFACTURING, INC. | 8/22/00 |
| 21. | 75-634 | ENALAPRILAT INJECTION 1.25 MG/ML (VIALS) | BEDFORD LABORATORIES | 8/22/00 |
| 22. | 75-606 | NORTRIPTYLINE HYDROCHLORIDE ORAL SOLUTION, USP 10 MG (BASE)/ML | PHARMACEUTICAL ASSOCIATES, INC. | 8/23/00 |
| 23. | 75-220 | DESMOPRESSIN ACETATE INJECTION 4 mcg/mL | ABBOTT LABORATORIES | 8/28/00 |
| 24. | 75-734 | HYDROXYUREA TABLETS 1 G | BARR LABORATORIES, INC. | 8/29/00 |
| 25. | 75-792 | PROPRANOLOL HYDROCHLORIDE INJECTION, USP 1 MG/ML | BEDFORD LABORATORIES | 8/29/00 |

# Office of Generic Drugs ANDAs Tentative Approvals



*08-Sep-00*

| | | | | |
|---|---|---|---|---|
| 1. | 75-572 | BUSPIRONE HYDROCHLORIDE TABLETS, USP 5 MG 10 MG 15 MG | KV PHARMACEUTICAL CO. | 8/4/00 |
| 2. | 75-722 | LORATADINE TABLETS 10 MG | TEVA PHARMACEUTICALS USA | 8/22/00 |
| 3. | 75-184 | PACLITAXEL INJECTION 6 MG/ML | BAKER NORTON PHARMACEUTICALS, INC. | 8/28/00 |

# *Office of Generic Drugs Approved Drugs Log - First Time Generic*

| *ANDA No* | *Established Name/Dosage Form and Stregnth* | *Applicant* | *SUB Date* | *TA Date* | *AP Date* |
|---|---|---|---|---|---|
| 75-722 | LORATADINE TABLETS 10 MG | TEVA PHARMACEUTICALS USA | 10/14/99 | 8/22/00 | |
| 75-184 | PACLITAXEL INJECTION 6 MG/ML | BAKER NORTON PHARMACEUTICALS | 8/8/97 | 8/28/00 | |
| 74-726 | POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS, USP 10 MEQ | UPSHER-SMITH LABORATORIES, INC. | 8/5/99 | | 8/9/00 |
| 75-606 | NORTRIPTYLINE HYDROCHLORIDE ORAL SOLUTION, USP 10 MG (BASE)/ML | PHARMACEUTICAL ASSOCIATES, INC | 3/23/99 | | 8/23/00 |
| 75-734 | HYDROXYUREA TABLETS 1 G | BARR LABORATORIES, INC. | 11/12/99 | | 8/29/00 |

# *Office Of Generic Drugs Supplement Approvals*



| | | | |
|---|---|---|---|
| 1. 75-155 S-010 | ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS 120 MG | KREMERS URBAN | 8/4/00 |
| 2. 40-094 S-008 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS, USP 10 MG/660 MG | WATSON LABORATORIES, INC. | 8/8/00 |
| 3. 74-726 S-001 | POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS, USP 10 MEQ | UPSHER-SMITH LABORATORIES, INC. | 8/9/00 |